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Thrombelastography in Horses with Acute Gastrointest inal Disease
K.L. Epstein, B.M. Brainard, S.E. Gomez-Ibanez, M.A.F. Lopes, M.H. Barton, and J.N. Moore
Background: Coagulopathies in horses with gastrointestinal disease are frequently identified and associated with morbidity
and fatality.
Objective: Determine if thrombelastography (TEG) identifies abnormalities associated with lesion type, presence of sys-
temic inflammatory response syndrome (SIRS), morbidity, and fatality more consistently than traditional coagulation testing.
Animals: One-hundred and one horses examined for gastrointestinal disease and 20 healthy horses.
Methods: TEG, tissue factor (TF)-TEG, and traditional coagulation panels parameters and percentages of horses with
coagulopathies were compared for lesion type, presence of SIRS, complications, and survival.
Results: Changes in individual parameters and increased incidence of coagulopathies were associated with fatality
(R, P 5 .007; k-value [K], P 5 .004; clot lysis [CL]30, P 5 .037; CL60, P 5 .050; angle [Ang], P 5 .0003; maximum amplitude
[MA], P 5 .006; lysis [Ly]30, P 5 .042; Ly60, P 5 .027; CI, P 5 .0004;  2 TEG coagulopathies, P 5 .013;  3 TEG coagulo-
pathies, P5 .038; TF-R, P5 .037; TF-K, P5 .004; TF-CL30, Po .0001; TF-CL60, Po .0001; TF-Ang, P5 .005; TF-Ly30,
P 5 .0002; TF-Ly60, P o .0001; TF-CI, P 5 .043;  1 TF-TEG coagulopathies, P 5 .003;  2 TF-TEG coagulopathies,
P 5 .0004; prothrombin tme [PT], P o .0001; activated partial throboplastin time [aPTT], P 5 .021), inflammatory lesions
(MA, P 5 .013; TF-CL30, P 5 .033; TF-CL60, P 5 .010; TF-Ly60, P 5 .011;  1 TF-TEG coagulopathy, P 5 .036;
 2 TF-TEG coagulopathy, P 5 .0007; PT, P 5 .0005; fibrinogen, P 5 .019), SIRS (MA, P 5 .004; TF-CL30, P 5 .019;
TF-CL60, P 5 .013; TF-Ly30, P 5 .020; TF-Ly60, P 5 .010; PT, P o .0001; aPTT, P 5 .032; disseminated intravascular
coagulation, P5 .005), and complications (ileus: aPTT, P5 .020; diarrhea: TF-CL30, P5 .040; TF-Ly30, P5 .041; thrombo-
phlebitis: 1 TF-TEG coagulopathy, P5 .018; laminitis: MA, P5 .004; CL60, P5 .045; CI, P5 .036; TF-MA, P5 .019; TF-
TEG CI, P 5 .019). Abnormalities in TEG and TF-TEG parameters were indicative of hypocoagulation and hypofibrinolysis.
Conclusions and Clinical Importance: TEG identifies changes in coagulation and fibrinolysis associated with lesion type,
SIRS, morbidity, and fatality in horses with gastrointestinal disease.
Key words: Coagulopathy; Point-of-care coagulation testing; Viscoelastic coagulation testing.
C
oagulopathies are common in horses with gastroin-
testinal disease, because systemic inflammatory
responses can activate coagulation.1 Abnormalities in
a variety of tests evaluating coagulation times, markers
of recent coagulation, and anticoagulant factors, in
addition to factors associated with fibrinolysis or inhibi-
tion of fibrinolysis are identified and associated with
morbidity and case fatality rate.2–19 Horses with gastro-
intestinal disease, especially severe disease, have evidence
of recent coagulation and fibrinolysis with concurrent
evidence of decreased procoagulant and profibrinolytic
factors.2–4,7,8,12–15,17–19 These changes are consistent with
activation and subsequent consumption of coagulation
and fibrinolytic factors. Once evidence of consumption
is present, conventional testing cannot determine the
balance between activation and consumption, and thus,
whether a horse is hyper- or hypocoagulable and hyper-
or hypofibrinolytic.
Thrombelastography (TEG) is a whole-blood, point-
of-care coagulation assay that provides information on
the kinetic and mechanical properties of a clot as it
forms, matures, and undergoes fibrinolysis. The use of
whole blood allows evaluation of cellular and plasma
components of coagulation concurrently, whereas typi-
cal coagulation tests only assess alterations in plasma
components. TEG might offer a more complete picture
of the balance of coagulation in individual animals by
providing a global assessment of coagulation. TEG has
been used to assess coagulopathies (hyper- and hypo-
coaguable states) in humans and animals.20–24 Reference
ranges for TEG in healthy horses with and without the
addition of tissue factor (TF) have been established.25–27
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Measured TEG parameters include reaction time
(R; time to the clot initiation), k value (K; the time for
the tracing to achieve a set clot strength), angle (Ang; the
rate of clot formation), and maximum amplitude
(MA; the greatest clot strength).20 Hypercoagulability is
characterized by decreases in R and K and increases in
Ang and MA, while hypocoagulability results in the op-
posite. TEG parameters that assess fibrinolysis include
clot lysis (CL30 and CL60; percent of MA at 30 and 60
minutes after reaching MA) and lysis (Ly30 and Ly60;
percent decrease in area under the curve compared with
MA at 30 and 60 minutes).20 Hyperfibrinolysis results in
decreased CL and increased Ly, while hypofibrinolysis
results in the opposite. TEG performed in a limited num-
ber of horses with gastrointestinal disease demonstrates
both hypercoagulability or hypocoagulability.a,27 These
results suggest that TEG might be helpful in determining
where a horse stands on the continuum between activation
and consumption of coagulation and fibrinolytic factors.
The objectives of this study were to identify relationships
between admission TEG and type of gastrointestinal lesion,
presence of systemic inflammatory response syndrome
(SIRS), morbidity (ileus, diarrhea, fever, thrombophlebitis,
and laminitis), and fatality in horses with gastrointestinal
disease. Additionally, the relationships were compared with
those identified with a traditional coagulation panel. These
objectives were formulated to test the hypotheses that
abnormalities detected on admission TEG would be asso-
ciated with lesion type, presence of SIRS, morbidity, and
fatality, and that TEG performed with or without TF




This study was a prospective clinical evaluation. Adult horses
(41 year) admitted to the University of Georgia Veterinary Teach-
ing Hospital between July 2007 and July 2008 for emergency
evaluation of gastrointestinal disease were eligible for inclusion.
The study was approved by the Institutional Animal Care and Use
Committee of the University of Georgia and written informed con-
sent for study participation was obtained from all owners.
Blood samples were obtained within 2 hours of admission. Horses
that had received blood products or synthetic colloids as part of initial
therapy in hospital or before referral were excluded because of the po-
tential for interactions with coagulation. Analysis of medical records
was performed once horses were discharged or euthanized.
Sampling Technique
Whole blood was collected by an experienced veterinarian via
clean jugular venipuncture. The jugular vein used had no indwelling
catheter in place and was free of palpable or visible evidence of
thrombus, phlebitis, or thrombophlebitis. A 19G 3/4 in. butterfly
catheterbwas used to collect the blood into a syringe.cBlood was then
transferred with a fresh 18G 1 in. needle to 4 vacuum-evacuated
tubes containing 3.2% citrate,d resulting in a final citrate : blood ratio
of 1 : 9 (TEG, prothrombin time [PT], activated partial throboplastin
time [aPTT], fibrinogen, antithrombin [AT],  platelet count), and
1 vacuum-evacuated tube containing soy trypsin (fibrin degradation
products [FDP]).d
TEG
TEG was performed with 2 channels of a thrombelastographe
with (TF-TEG) and without (TEG) TF activation as described pre-
viously.25 Output of the TEG was recorded on a desktop computer
by the TEG Analytical software.f Clotting index (CI) is a parameter
that can be calculated from measured TEG parameters (R, K, Ang,
andMA) to estimate the overall tendency of the patient to be hyper-
(increase) or hypocoagulable (decrease). CI was calculated as
0.1227R1 0.0092K1 0.1655MA  0.0241Ang  5.022.20
Coagulation Profile
Coagulation profiles included PT, aPTT, platelet count, AT,
fibrinogen, and FDP. Platelet counts were performed as part of a
CBCg during the routine clinical evaluation of client-owned ani-
mals. If thrombocytopenia was detected, the platelet count was
repeated on a citrated sample to rule out EDTA-induced pseudo-
thrombocytopenia.h,28 Citrated samples for PT, aPTT, fibrinogen,
and AT were centrifuged immediately after collection at 1,500  g
for 10 minutes at 41C. Plasma was harvested and frozen at 801C
before batch analysis. The PT, aPTT, and fibrinogen analyses were
performed with optical measurement techniques.i AT was assayed
using a chromogenic assay.j The tube containing soy trypsin sat at
room temperature for 1 hour, and was then centrifuged at 1,500 g
for 10 minutes at 41C. The serum was collected and frozen at801C
until batch analysis. FDP concentrations were measured by a semi-
quantitative latex agglutination technique.k
Coagulopathy
Twenty healthy, adult, university-owned horses were sampled as
described for the study population to establish reference values. Study
horses were defined as having a coagulopathy based on deviation from
this reference population. Based on results of the coagulation profile,
horses were grouped as having disseminated intravascular coagulation
(DIC) or noDIC. DICwas defined as at least 3 abnormal coagulation
parameters.5 An abnormal coagulation parameter was defined as at
least 2 standard deviations (SD) above the mean for PT and aPTT, at
least 2 SD below the mean for fibrinogen, AT, and platelet count,
and FDP exceeding the highest FDP concentration recorded in the
reference population. Based on results of the TEG and TF-TEG,
horses were grouped as having a coagulopathy of 1, 2, or 3 TEG or
TF-TEG parameters. A coagulopathy of a TEG or TF-TEG param-
eter was defined as at least 2SD above or below the mean for all
parameters. The direction of change and incidence of abnormality for
each parameter were recorded.
Lesion Type
Horses were grouped into 1 of 4 lesion categories: nonstrangulating
medical (NSM), nonstrangulating surgical (NSS), strangulating (S),
and inflammatory (I). The diagnosis listed in the medical record de-
termined by the clinician managing the case was used to categorize
lesion type. Minimum database in horses presenting for gastrointesti-
nal disease included physical examination, nasogastric intubation,
rectal examination, PCV and TS, CBC, and blood gas w/ electrolytes
with further diagnostics performed at the discretion of the admitting
clinician. If available, surgical or necropsy reports were used to con-
firm the listed diagnosis.
Horses with NSM lesions without evidence of an underlying
inflammatory or strangulating lesion on clinical or necropsy evalu-
ation were managed with medical therapy. Horses with NSS lesions
without evidence of an underlying inflammatory or strangulating
lesion at the time of surgery were managed with surgical exploration
and treatment. Horses with S lesions had evidence of obstruction to
intestinal perfusion at surgery or necropsy. Necessity for resection
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and anastomosis was not required for inclusion in the strangulating
category. Horses with inflammatory lesions had evidence of inflam-
matory intestinal diseases based on the combination of clinical
examination (including elevated temperature [ 101.51F], large
quantities of nasogastric reflux, diarrhea, mucus membrane appear-
ance, transabdominal ultrasound [changes in contents—fluid,
changes in wall thickness]), clinical pathology (WBC count [le-
ucopenia, left shift, leukocytosis], abdominocentesis analysis),
surgical, or necropsy findings.
SIRS
Horses were classified as having SIRS if they had at least 2 of the
following abnormalities on physical examination at presentation:
T  101.51F, HR  60 bpm, RR  30 bpm, WBC count  12,500
or 4,500 cells/mL, and  10% band neutrophils. These criteria are
an adaptation of SIRS criteria used in foals29 to adult horses.
Complications
Medical records were examined to determine the incidence of the
following complications throughout hospitalization: ileus, diarrhea,
fever, thrombophlebitis, and laminitis. Ileus was defined as 8L re-
flux single time or20L in 24 hours.30Diarrhea was defined as liquid
feces that were unable to remain on top of shavings. Fever was defined
as a temperature of101.51F. Thrombophlebitis was defined as iden-
tification of swelling over a jugular vein with one or more of the
following: pain, heat, and/or decreased/absent flow through the vessel.
Laminitis was defined as acute lameness with one or more of the fol-
lowing: standing with forelimbs extended in front and the majority of
weight-bearing on the hindlimbs, increased digital pulses, increased
hoof temperature, clefting at the coronary band, positive to hoof
testers, or radiographic findings consistent with laminitis.
Survival
Survival was defined as survival to hospital discharge. Reason for
nonsurvival (cost versus prognosis; euthanasia versus death) was
not determined.
Statistical Analysis
Statistical analysis was performed by commercial statistical anal-
ysis software.l Descriptive statistics were performed on the
coagulation profiles, TEG, and TF-TEG parameters. Means, stan-
dard deviations, and ranges were calculated. Normality was
assessed by the Shapiro-Wilk test.
TEG and coagulation profile values were compared for the fol-
lowing groups: horses that survived versus those that did not
survive, SIRS versus no SIRS, ileus versus no ileus, diarrhea versus
no diarrhea, fever versus no fever, thrombophlebitis versus no
thrombophlebitis, and laminitis versus no laminitis. These compar-
isons were done by a Student’s t-test if results were normally
distributed or with a Wilcoxon’s sum-rank test if they were not nor-
mally distributed. TEG and coagulation profile values were
compared between study horses in different disease groups by
ANOVA or Kruskal-Wallis’ test depending on data distribution.
Significance was set at P  .05.
The proportions of horses with DIC, TEG coagulopathy, and
TF-TEG coagulopathy were compared between horses in the fol-
lowing categories: survival versus no survival, SIRS versus no SIRS,
ileus versus no ileus, diarrhea versus no diarrhea, fever versus no
fever, thrombophlebitis versus no thrombophlebitis, and laminitis
versus no laminitis with Fischer’s exact test. The proportions of
horses with DIC, TEG coagulopathy, and TF-TEG coagulopathy
were compared between horses by lesion type with w2-test. Signifi-
cance was set at P  .05.
Results
Study Population
One-hundred and one horses admitted for emergency
evaluation of gastrointestinal disease were included in the
study. Horses included a variety of breeds (28 Quarter
Horses [QH], 16 Thoroughbreds, 15 Warmbloods, 9 Ara-
bian, 7 Paint, 5 Appaloosa, 4 Paso Fino, 4 Pony, 3
Saddlebred, 2 Tennessee Walking Horse, 2 mixed breed, 1
each of 6 other breeds). There were 54 geldings, 41 mares,
and 6 stallions. Horses were 1–36 years old (11.9  6.6
years; median 10 years). The 20 healthy adult horses used
to determine reference ranges had an average age of 9.5 
4.8 years and an age range of 2–20 years. These horses also
represented a selection of breeds (15 QH, 2 Paint, 1 each of
3 other breeds) and sex (10 mares, 7 geldings, 3 stallions).
Most horses had received one or more medications as
part of their initial treatment and evaluation in the field,
and to facilitate examination at admission. Common med-
ications received before referral included, but were not
limited to, sedatives (xylazine 0.2–1mg/kg, detomidine
0.005–0.02mg/kg, butorphanol0.01–0.02mg/kg), non-
steroidal anti-inflammatory drugs before referral (flunixin
meglumine 1mg/kg), and fluids administered IV.
Coagulopathy
Six horses met the criteria for DIC. There were 35, 29,
and 16 horses that had coagulopathies evidenced as 1,
2, and 3 TEG parameters, respectively. There were 42,
22, and 12 horses that had coagulopathies indentified as
1, 2, and 3 TF-TEG parameters, respectively (Table 1).
For TEG coagulopathies, CL60 (24 increased) and
Ly60 (24 decreased) were the most common parameters
affected, followed by K (12 increased), R (10 increased),
MA (2 increased, 4 decreased) and Ang (6 decreased),
CL30 (1 decreased), and Ly30 (1 increased).
For TF-TEG coagulopathies, Ang was the most com-
mon parameter affected (1 increased, 18 decreased),
followed by R (15 increased, 3 decreased), K (17 increased),
CL60 (15 increased),MA (1 increased, 12 decreased), CL 30
(1 decreased), Ly30 (1 increased), and Ly60 (1 increased).
Lesion Type
There were 34 NSM horses (18 without specific diagno-
sis, 5 ileal impactions, 4 left dorsal displacements of the
large colon, 2 large colon impactions, and 1 each cecal
impaction, small colon impaction, jejunal stricture, sand
colic, and right dorsal displacement of the large colon), 18
NSS horses (6 right dorsal displacements of the large co-
lon, 3 left dorsal displacements of the large colon, 3 sand
impactions, 2 other large colon displacement, and 1 each
fecolith, enterolith, ileal impaction with right dorsal dis-
placement of the large colon, and no identified lesion), 26
S horses (9 small intestinal strangulating lipomas, 5 large
colon volvuluses, 2 epiploic foramen entrapments, 2 small
intestinal volvuluses, 2 small intestinal strangulations
within a rent in the omentum, 2 ischemic small intestinal
segments of unknown cause, and 1 each gastrosplenic
entrapment, mesodiverticular band strangulation of small
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intestine, large colon ischemia of unknown cause, and
small colon strangulating lipoma), and 23 I horses (6
enteritis, 7 colitis, 6 intestinal rupture, 3 typhlocolitis, and
1 enterocolitis).
TEG-MA was decreased in horses with inflammatory
lesions compared with horses with NSM and NSS lesions
(P 5 .012) (Table 2). TF-TEG CL-30 and CL-60 were
increased in horses with inflammatory lesions compared
with horses with NSS lesions (P 5 .033 and P 5 .010)
(Table 3). TF-TEG LY-60 was decreased in horses with
inflammatory lesions compared with horses with NSS
lesions (P 5 .011). One or more TF-TEG coagulopathy
was associated with lesion type (P 5 .0361; 9/34 [26.5%]
NSM, 7/18 [38.9%] NSS, 11/26 [42.3%] S, 15/23 [65.2%]
I). Two or more TF-TEG coagulopathies was associated
with lesion type (P 5 .0007; 1/34 [2.9%] NSM, 3/18
[16.7%] NSS, 7/26 [26.9%] S, 15/23 [65.2%] I). TEG co-
agulopathies and 3 TF-TEG were not associated with
lesion type.
Analysis of coagulation profiles revealed prolongation
of PT in I (10.90  1.41 seconds; normal horses: 9.57 
0.27 seconds) and S (10.26  0.69 seconds) lesions com-
pared with NSM (9.74  0.50 seconds) lesions (P5 .0005)
and an increase in fibrinogen concentration in horses with I
(385 107mg/dL, normal horses: 336 62mg/dL) lesions
compared with horses with NSM (301  62mg/dL) and S
(316 122mg/dL) lesions (P5 .019—both). DIC was not
associated with lesion type.
SIRS
There was insufficient information in medical records for
SIRS classification in 6 horses. Of the remaining 95 horses,
27 horses had evidence of SIRS (1 NSM, 3 NSS, 7 S, 16 I).
TEGMAwas decreased in horses with SIRS (P5 .004)
(Table 4). TF-TEG CL30 and CL60 were increased in
horses with SIRS (P5 .019 and P5 .013). TF-TEGLY30
and LY60 were decreased in horses with SIRS (P 5 .020
and P 5 .010). TEG and TF-TEG coagulopathies were
not associated with the presence of SIRS.
Analysis of coagulation profiles revealed a prolongation
of PT and aPTT in horses with SIRS (10.97  1.19 and
62.8  12.7 seconds, respectively; aPTT normal horses:
59.0  8.0 seconds) compared with horses without
SIRS (9.91  0.56 and 57.2  8.1 seconds, respectively)
(P o .0001 and P 5 .032). DIC was associated with the
presence of SIRS (P 5 .005). All horses with DIC
had SIRS.
Table 1. TEG and TF-TEG in normal horses and resulting definition for coagulopathy of each parameter.
R (min) K (min) Ang (1) MA (mm) CL30 (%) LY30 (%) CL60 (%) LY60 (%)
TEG
Normal 16.2 (5.8) 5.7 (3.7) 42.5 (13.2) 61.7 (8.4) 97.3 (2.0) 0.7 (0.7) 90.3 (3.7) 3.8 (1.7)
Coagulopathy o4.7 o0 (N/A) o16.0 o44.8 o93.3 o0 (N/A) o83.0 o0.3
427.8 413.1 469.0 478.6 4100 (N/A) 42.1 497.7 47.3
N 20 20 20 20 18 18 15 15
TF-TEG
Normal 6.9 (1.3) 3.2 (1.1) 52.8 (7.5) 62.9 (5.2) 97.9 (1.6) 0.5 (0.5) 91.5 (2.85) 3.0 (1.5)
Coagulopathy o4.4 o1.0 o37.8 o52.6 o94.7 o 0(N/A) o85.9 o0 (N/A)
49.4 45.4 467.8 473.3 4100 (N/A) 41.6 497.1 46.1
N 20 20 20 20 20 20 18 18
Mean (SD).
TEG, thrombelastography; TF-TEG, thrombelastography performed with tissue factor activation; R, reaction time; K, k value; Ang, angle;
MA, maximum amplitude; CL, clot lysis; Ly, lysis; 30, 30 minutes after reaching MA; 60, 60 minutes after reaching MA.
Table 2. TEG parameters by lesion type in horses with gastrointestinal disease.
R (min) K (min) Ang (1) MA (mm) CL30 (%) LY30 (%) CL60 (%) LY60 (%) CI
Normal 16.2 (5.8) 5.7 (3.7) 42.5 (13.2) 61.7 (8.4) 97.3 (2.0) 0.7 (0.7) 90.3 (3.7) 3.8 (1.7) 6.2 (1.4)
NSM 18.1 (7.6) 6.5 (3.7) 38.2 (12.0) 62.1 (7.9)a 99.1 (1.3) 0.2 (0.3) 93.7 (4.1) 1.9 (1.6) 0.1 (2.0)
8.5–43.9 2.3–17.8 12.6–59.8 46.5–79 94.9–100 0–1.6 83.4–100 0–6.7 6.0–3.2
N 34 33 33 33 30 30 26 26 33
NSS 18.8 (6.9) 7.5 (4.7) 36.6 (10.9) 62.0 (9.0)a 97.8 (2.4) 0.7 (1.1) 93.0 (5.7) 2.7 (2.4) 0.1 (1.5)
8.7–34.4 3.3–20.1 15–49.4 42.8–78.6 92.1–100 0–4.6 83.7–100 0–6.8 3.0–1.5
N 17 17 17 17 17 17 17 17 17
S 17.0 (6.8) 8.4 (9.9) 36.7 (13.8) 59.6 (6.9)a,b 99.1 (1.3) 0.2 (0.3) 94.6 (3.8) 1.7 (1.5) 0.7 (3.3)
10.5–37.2 3.2–46.8 5.7–52.4 45.7–71.1 95.5–100 0–1.2 87.8–100 0–5.2 13.4–1.7
N 23 23 23 22 21 21 21 21 23
I 18.6 (7.1) 7.8 (4.7) 33.0 (12.9) 54.8 (9.6)b 99.2 (1.3) 0.1 (0.3) 95.3 (4.2) 1.5 (1.6) 1.2 (2.2)
5.9–36.5 1.8–23.6 10.5–61.4 35.8–70.8 95.8–100 0–1 86.6–100 0–5.3 5.3–2.3
N 22 22 22 22 22 22 21 21 22
NSM, nonstrangulatingmedical; NSS, nonstrangulating surgical; S, strangulating; I, inflammatory; TEG, thrombelastography; R, reaction time;
K, k value; Ang, angle; MA, maximum amplitude; CL, clot lysis; Ly, lysis; 30, 30 minutes after reaching MA; 60, 60 minutes after reaching MA.
Mean (SD) and range. Superscripts denote significant differences between lesion types (Po .05). Normal values given for comparison.
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Complications
Information available in medical records was sufficient
to determine the presence of complications in at least 71
horses. There were 28 horses with complications (17 with
1 complication; 7 with 2 complications; and 4 with 3
complications). There were 14 horses with ileus, 10
horses with diarrhea, 9 horses with fever, 8 horses with
thrombophlebitis, and 2 horses with laminitis.
There was no association between the occurrence
of ileus and any TEG or TF-TEG parameters or co-
agulopathies or DIC. Analysis of coagulation profiles
revealed a relative prolongation of aPTT in horses with
ileus compared with those without (64.4  10.2 versus
57.6  9.8 seconds; P 5 .023).
Analysis of TEG parameters revealed no association
with the presence of diarrhea. Analysis of TF-TEG
parameters in horses with diarrhea revealed a relatively de-
creased CL30 and increased LY30 (P 5 .040 and .041,
respectively) compared with those without diarrhea. Anal-
ysis of coagulation profiles revealed no association with
diarrhea. There was no association between the presences
of diarrhea and TEG or TF-TEG coagulopathies or DIC.
There was no association between the presence of fever
and any TEG, TF-TEG, or coagulation profile parameters.
There was no association between thrombophlebitis
and any TEG, TF-TEG, or coagulation profile para-
meter. The presence of one or more TF-TEG coagulo-
pathies was associated with thrombophlebitis (P 5 .018;
6/8 [75%] thrombophlebitis, 19/64 [30%] no thrombo-
phlebitis). There was no association between 2 or 3
TF-TEG coagulopathies, any TEG coagulopathies, or
DIC and thrombophlebitis.
Table 3. TF-TEG parameters by lesion type in horses with gastrointestinal disease.
R (min) K (min) Ang (1) MA (mm) CL30 (%) LY30 (%) CL60 (%) LY60 (%) CI
Normal 6.9 (1.3) 3.2 (1.1) 52.8 (7.5) 62.9 (5.2) 97.9 (1.6) 0.5 (0.5) 91.5 (2.85) 3.0 (1.5) 5.0 (0.8)
NSM 7.1 (1.6)a 3.6 (0.8) 48.4 (6.1) 61.0 (5.9) 99.1 (1.2)c,d 0.2 (0.3) 93.2 (2.7)e,f 2.1 (1.2)g,h 2.2 (1.0)
4.2–11.2 2–5.6 37.5–65 47.9–73.6 95.8–100 0–1.2 88.6–100 0–4.8 0.5–4.7
N 34 34 34 34 30 30 28 28 34
NSS 8.3 (3.5)a,b 4.1 (1.6) 46.3 (10.3) 61.0 (6.4) 98.6 (1.0)c 0.3 (0.3) 92.1 (2.6)e 2.6 (1.1)g 2.0 (1.0)
4.6–21.3 1.8–7.3 24.6–60 49.6–71 96.6–100 0–1.1 88.5–99.4 0–4.3 0.2–3.3
N 18 18 18 18 18 18 18 18 18
S 7.5 (2.5)a,b 4.4 (1.8) 45.0 (8.9) 59.5 (8.0) 99.1 (1.2)c,d 0.2 (0.3) 94.3 (3.0)e,f 1.7 (1.3)g,h 2.0 (1.4)
4.7–14.9 2.6–9.1 24.5–58 35.2–71.2 95.7–100 0–1.2 87.8–99.7 0–5.1 2.2–4.3
N 26 26 26 26 25 25 25 25 26
I 8.6 (2.8)b 5.1 (2.8) 43.7 (11.7) 56.7 (9.3) 99.3 (1.4)d 0.2 (0.4) 95.3 (4.1)f 1.5 (1.6)h 1.3 (1.5)
3.2–18.1 1.3–12.3 19.6–69.2 28.8–70.8 94.3–100 0–1.8 86.6–100 0–6.2 2.5–3.5
N 23 23 23 23 23 23 23 23 23
NSM, nonstrangulating medical; NSS, nonstrangulating surgical; S, strangulating; I, inflammatory; TF-TEG, thrombelastography per-
formed with tissue factor activation; R, reaction time; K, k value; Ang, angle; MA, maximum amplitude; CL, clot lysis; Ly, lysis; 30, 30
minutes after reaching MA; 60, 60 minutes after reaching MA.
Mean (SD) and range. Superscripts denote significant differences between lesion types (Po .05). Normal values given for comparison.
Table 4. TEG and TF-TEG parameters in horses with gastrointestinal disease with and without evidence of SIRS.
R (min) K (min) Ang (1) MA (mm) CL30 (%) LY30 (%) CL60 (%) LY60 (%) CI
TEG
Normal 16.2 (5.8) 5.7 (3.7) 42.5 (13.2) 61.7 (8.4) 97.3 (2.0) 0.7 (0.7) 90.3 (3.7) 3.8 (1.7) 6.2 (1.4)
No SIRS 17.8 (7.2) 7.1 (6.3) 37.9 (12.4) 61.6 (8.0)a 98.7 (1.7) 0.3 (0.78) 93.6 (4.3) 2.2 (1.8) 0.2 (2.5)
6.6–43.9 1.8–46.8 5.7–61.4 42.8–79.0 92.15–100 0–4.6 83.4–100 0–6.7 13.4–3.2
N 65 64 64 63 61 61 58 58 65
SIRS 17.6 (5.6) 7.7 (5.6) 34.1 (12.4) 55.9 (8.6)b 99.2 (1.5) 0.2 (0.4) 95.1 (4.5) 1.6 (1.8) 0.8 (1.9)
5.9–28.6 2.6–25 10.5–57.3 35.8–70.8 94.1–100 0–1.8 84.3–100 0–6.8 4.8–2.2
N 26 26 26 26 24 24 24 24 26
TF-TEG
Normal 6.9 (1.3) 3.2 (1.1) 52.8 (7.5) 62.9 (5.2) 97.9 (1.6) 0.5 (0.5) 91.5 (2.85) 3.0 (1.5) 5.0 (0.8)
No SIRS 7.6 (2.6) 4.0 (1.5) 46.6 (8.8) 60.2 (6.7) 98.8 (1.3)c 0.2 (0.4)e 93.0 (2.9)g 2.2 (1.3)i 2.0 (1.1)
3.2–21.3 1.3–9.1 24.5–69.2 35.2–73.6 94.3–100 0–1.8 86.6–100 0–6.2 2.2–4.7
N 68 68 68 68 63 63 62 62 68
SIRS 8.1 (2.6) 4.3 (1.6) 46.6 (8.8) 58.7 (7.4) 99.5 (0.8)d 0.1 (0.2)f 95.0 (3.5)h 1.4 (1.2)j 1.7 (1.2)
3.7–18.1 2.6–10.9 25–58 40.7–10.8 96.6–100 0–0.9 88.8–100 0–4.4 1.2–3.6
N 27 27 27 27 27 27 26 26 27
TEG, thrombelastography; TF-TEG, thrombelastography performed with tissue factor activation; R, reaction time; K, k value; Ang, an-
gle; MA, maximum amplitude; CL, clot lysis; Ly, lysis; 30, 30 minutes after reaching MA; 60, 60 minutes after reaching MA; SIRS, systemic
inflammatory response syndrome.
Mean (SD) and range. Superscripts denote significant differences between SIRS and No SIRS (Po .05). Normal values given for comparison.
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Analysis of TEG parameters in horses that developed
laminitis revealed a relative decrease in MA, CL60, and
CI (P5 .004, .045, and .036, respectively) compared with
those without laminitis. Analysis of TF-TEG parameters
revealed a decrease in MA and CI (P 5 .019 and .019,
respectively) in horses with laminitis compared with
those without laminitis. Analysis of coagulation profiles
revealed no association with laminitis. There was no as-
sociation between TEG coagulopathies, TF-TEG
coagulopathies, or DIC and laminitis.
Survival
Twenty-one horses did not survive to discharge. TEGR,
K, CL30, and CL60 were increased in nonsurvivors (P 5
.007, .004, .037, and .050, respectively) (Table 5). TEG
Ang, MA, Ly30, Ly60, and CI were decreased in nonsur-
vivors (P5 .0003, .006, .042, .027, and .0004, respectively).
TF-TEG R, K, CL30, and CL60 were increased in non-
survivors (P 5 .037, .004, o .0001, and o .0001,
respectively). TF-TEG Ang, Ly30, Ly60, and CI were de-
creased in nonsurvivors (P 5 .005, .0002, o .0001, and
.043, respectively). The presence of 2 or more TEG co-
agulopathies (11/21 [52.4%] nonsurvivors; 18/80 [22.5%]
survivors; P 5 .013),  3 TEG coagulopathies (7/21
[33.3%] nonsurvivors; 9/80 [11.3%] survivors; P 5 .038),
 1 TF-TEG coagulopathies (15/21 [71.4%] nonsurvivors;
27/80 [33.8%] survivors; P 5 .003), and  2 TF-TEG co-
agulopathies (11/21 [52.4%] nonsurvivors; 11/80 [13.8%]
survivors; P 5 .0004) were associated with nonsurvival.
There was no association between1 TEG coagulopathies
or 3 TF-TEG coagulopathies and survival.
Analysis of coagulation profiles revealed a prolonga-
tion of PT and aPTT in nonsurvivors (11.19  1.51 and
64.8  12.0 seconds, respectively) compared with survi-
vors (10.01  0.72 and 57.9  9.3 seconds, respectively)
(Po .0001 and P 5 .021, respectively). The presence or
absence of DIC was not associated with survival.
Discussion
The findings of this study support our hypotheses that
TEG performed at admission identified abnormalities
associated with inflammatory lesions, SIRS, the devel-
opment of diarrhea, thrombophlebitis, laminitis, and fa-
tality. The directions of change of TEG parameters were
consistent with hypocoagulation and hypofibrinolysis.
Depending on the balance within the horse, this could
result in tendencies toward bleeding or thrombosis. No
single parameter or number of coagulopathies identified
with TEG appears ideal for predicting outcome of horses
with colic.
Traditional coagulation testing in horses with gastro-
intestinal disease performed in previous studies revealed
evidence of consumption of coagulation factors mani-
fested by prolongation of coagulation times.2,4,6,8,11–15
Prolongation of coagulation times is likely secondary
to activation and subsequent consumption of coagula-
tion factors. Once activation and consumption have
begun, whether a patient is hypercoagulable or hypoco-
agulable depends on the balance between the two and
cannot be determined by traditional coagulation testing.
In our population, horses with severe gastrointestinal
disease have progressed to hypocoagulation, based on
TEG analysis, by the time of presentation.
Horses with gastrointestinal disease have an increase in
products of fibrinolysis with a concurrent decrease in plas-
minogen, which is most consistent with prior activation
and consumption of fibrinolytic enzymes.2,4,8,19 Addition-
ally, increases in inhibitors of fibrinolysis have been
identified.9,16 Inflammation in other species increases inhi-
bition of fibrinolysis by several mechanisms.31,32 These
findings suggest that the hypofibrinolysis identified by
Table 5. TEG and TF-TEG parameters in surviving and nonsurvivoring horses with gastrointestinal disease.
R (min) K (min) Ang (1) MA (mm) CL30 (%) LY30 (%) CL60 (%) LY60 (%) CI
TEG
Normal 16.2 (5.8) 5.7 (3.7) 42.5 (13.2) 61.7 (8.4) 97.3 (2.0) 0.7 (0.7) 90.3 (3.7) 3.8 (1.7) 6.2 (1.4)
Survivor 17.1 (65)a 6.4 (3.9)c 38.6 (11.5)e 61.0 (8.2)g 98.7 (1.7)j 0.3 (0.7)k 93.7 (4.3)m 2.1 (1.8)o 0.03 (1.8)q
6.6–43.9 1.8–25 11.5–61.4 35.8–79.0 92.1–100 0–4.6 83.4–100 0–6.8 6.0–3.2
N 77 76 76 76 73 73 69 69 77
Non-Survivor 21.9 (8.2)b 11.7 (10.3)d 27.3 (12.4)f 54.8 (9.3)h 99.6 (0.9)j 0.1 (0.2)l 96.1 (4.4)n 1.1 (1.5)p 2.3 (3.3)r
5.9–37.2 3.2–46.8 5.7–59.3 38.9–71.1 96.7–100 0–0.7 87.6–100 0–4.6 13.4–1.9
N 19 19 19 18 17 17 16 16 19
TF-TEG
Normal 6.9 (1.3) 3.2 (1.1) 52.8 (7.5) 62.9 (5.2) 97.9 (1.6) 0.5 (0.5) 91.5 (2.85) 3.0 (1.5) 5.0 (0.8)
Survivor 7.3 (1.7)a 4.0 (1.6)c 47.42 (8.9)e 60.2 (7.1) 98.8 (1.3)g 0.2 (0.4)i 93.0 (2.9)k 2.3 (1.3)m 2.1 (1.2)o
3.2–12.2 1.3–11.8 19.6–69.2 28.8–73.6 94.3–100 0–1.8 86.6–100 0–6.2 2.5–4.7
N 80 80 80 80 75 75 74 74 80
Non-Survivor 9.3 (4.3)b 5.3 (2.4)d 41.1 (8.6)f 57.6 (8.9) 99.9 (0.3)h 0.0 (0.0)j 97.0 (2.5)l 0.7 (0.7)n 1.3 (1.4)p
3.7–21.3 2.6–12.3 25–56.4 40.7–71 98.9–100 0–0.2 91.3–100 0–2.7 1.2–3.6
N 21 21 21 21 21 21 20 20 21
TEG, thrombelastography; TF-TEG, thrombelastography performed with tissue factor activation; R, reaction time; K, k value; Ang, an-
gle; MA, maximum amplitude; CL, clot lysis; Ly, lysis; 30, 30 minutes after reaching MA; 60, 60 minutes after reaching MA.
Mean (SD) and range. Superscripts denote significant differences between survivors and nonsurvivors (Po .05). Normal values given for
comparison.
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TEG in this study could be because of a combination of
consumption of fibrinolytic enzymes and increased inhibi-
tion of fibrinolysis.
Although TEG appears capable of identifying co-
agulopathies associated with severe gastrointestinal
disease, it is important to note that variability in tracings
was observed in the healthy horses and horses with gas-
trointestinal disease. Additionally, there was marked
overlap in the ranges of values for most parameters be-
tween horses in different categories. This variability is
similar to that previously reported in healthy horses.25,26
Thus, interpretation of single TEG tracing in a diseased
horse is difficult. It is possible that comparison of serial
TEG tracings performed in the same horse could lead to
more accurate conclusions.
In an attempt to reduce the impact of the variability,
horses were categorized by the number of parameters that
were outside of the reference range. No single number of
abnormalities was found to best for predicting outcome.
Although it would seem logical that an increasing number
of abnormalities would be more likely to be associated
with morbidity and case fatality rate, this was not this case
for lesion type, thrombophlebitis, or survival. This finding
is difficult to explain. Given that 5% of normal horses
would fall outside of the range of values we used to deter-
mine coagulopathies, it might be that horses with multiple
abnormalities are more likely to be the horses that would
be outliers under normal conditions.
In healthy horses and horses with gastrointestinal dis-
ease, variability ofmost parameters is decreased when TEG
is performed with TF (data from current study not pre-
sented).25 Although the decreased variability in TF-TEG
should make differences between groups easier to identify,
this was not obvious in the current study. This could be be-
cause of the coagulation abnormality being obscured by the
procoagulant activity of added TF. This could be particu-
larly true in horses with gastrointestinal disease because
they have lower concentrations of factor VII.11
Several limitations of this study should be considered
when interpreting the results. There were a small number
of horses with complications (laminitis [n 5 2]) in this
study. Thus, the study may be underpowered to identify
any associations between coagulopathies and complica-
tions and results should be interpreted with caution.
Additionally, no attempt was made to analyze the effect
of interactions between TEG parameters (ie, horses with
increased R are likely to have increased K) or groups (ie,
horses with inflammatory lesions are likely to have SIRS).
Another limitation of the study is that horses that did
not survive were not separated based on the reason the
owner elected euthanasia because of a poor prognosis
versus financial limitations. However, 20/21 horses that
were euthanized had a poor prognosis evidenced by a di-
agnosis of severe disease at surgery or necropsy,
diagnosis of gastrointestinal rupture on abdominocente-
sis, and failure of aggressive medical treatment, surgical
treatment, or both. Additionally, the inclusion of horses
euthanized for financial limitations results in horses with
less severe disease—and likely less severe coagulopathies-
in the nonsurvivor group could decrease the likelihood to
identify coagulopathies associated with survival.
Another limitation of the study is lack of control for
the potential effect of therapies administered before re-
ferral and between admission and sampling. Horses
that were treated with medications with the most well-
documented effects on coagulation, synthetic colloids
and plasma, were excluded. NSAID administration can
affect platelet function and coagulation.33–35 Nonselec-
tive cyclooxygenase inhibitors have minimal effect on
TEG in humans and dogs.35,36 Flunixin meglumine and
phenylbutazone are therefore unlikely to have a clinically
important impact on TEG. The effects of sedatives, fluid
administration, or both on coagulation are unknown.
The findings of this study indicate that TEG identifies
changes in coagulation and fibrinolysis associated with
lesion type, SIRS, morbidity, and fatality in horses with
gastrointestinal disease more frequently than traditional
coagulation tests. Abnormalities in TEG and TF-TEG
parameters were indicative of hypocoagulation and hypo-
fibrinolysis and suggest a consumptive coagulopathy.
However, the interhorse variability of TEG tracings
makes interpretation and clinical use of the test difficult.
Footnotes
aDunkel B, Chan D, Monreal L. Association between hypercoagul-
ability and decreased survival in horses with ischemic or
inflammatory gastrointestinal disease. J Vet Emerg Crit Care
2010;20:18 (absract).
bAbbott N, Chicago, IL
cMonoject, Covidien, Mansfield, MA
dVacutainer, Becton Dickinson, Franklin Lakes, NJ
eTEG 5000, Haemoscope, Niles, IL
f v. 4.2.95, Haemoscope
gBayer Advia 120, Seimen’s Healthcare Diagnostics Incorportated,
Deerfield, IL
hHeska CBC-Diff, Heska Corp, Loveland, CO
iACL 1000, Beckman-Coulter, Miami, FL
jAMAX, Trinity Biotech USA, St Louis, MO
kThrombo-Wellcotest, Remel, Atlanta, GA
l SAS V 9.2, SAS Institute Inc, Cary, NC
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